Evidence map›Paper›PMID 41918160›Full record

ArticleChembiochem : a European journal of chemical biology2026

Radioiodination of Two Carborane-Based Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation.

Jonas Schädlich, Martin Ullrich, Cathleen Haase-Kohn, Robert Wodtke, Sebastian Braun, Maximilian Molitor, Bettina Hofmann, Dieter Steinhilber, Klaus Kopka, Evamarie Hey-Hawkins and 2 more

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jonas SchädlichInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID https://orcid.org/0009-0002-4550-0394
Martin UllrichInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID https://orcid.org/0000-0001-6104-6676
Cathleen Haase-KohnInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID https://orcid.org/0000-0002-5032-5095
Robert WodtkeInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID https://orcid.org/0000-0001-7462-7111
Sebastian BraunInstitute of Bioanalytical Chemistry, Centre for Biotechnology and Biomedicine (BBZ), Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Germany.ORCID https://orcid.org/0000-0001-7693-318X
Maximilian MolitorInstitute of Pharmaceutical Chemistry, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0002-1215-466X
Bettina HofmannInstitute of Pharmaceutical Chemistry, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0002-8323-3840
Dieter SteinhilberInstitute of Pharmaceutical Chemistry, Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0001-8905-5208
Klaus KopkaInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID https://orcid.org/0000-0003-4846-1271
Evamarie Hey-HawkinsInstitute of Bioanalytical Chemistry, Centre for Biotechnology and Biomedicine (BBZ), Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Germany.ORCID https://orcid.org/0000-0003-4267-0603
Jens PietzschInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID https://orcid.org/0000-0002-1610-1493
Markus LaubeInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID https://orcid.org/0000-0003-4916-3794

Funding

Deutsche Forschungsgemeinschaft Grant HE 1376/54-1Deutsche Forschungsgemeinschaft PI 304/7-1
6 · The paper itself

Abstract

Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) are key enzymes in prostanoid and leukotriene signaling and are overexpressed in various cancers, correlating with malignancy and metastasis. This renders them promising molecular targets for radiotracer development. In this study, isomeric closo-dicarbadodecaborane(12)-based dual COX-2/5-LO inhibitors (1 and 2) served as scaffolds for iodine-123-labeling. Iodinated derivatives 3 and 4 inhibited 5-LO more potently than COX-2 in vitro (IC

Indexed as

Arachidonate 5-LipoxygenaseBoranesCyclooxygenase 2Cyclooxygenase 2 InhibitorsLipoxygenase InhibitorsAnimalsCarboranesCell Line, TumorHalogenationHumansIodine RadioisotopesMiceTissue DistributionArachidonate 5-LipoxygenaseBoranesCarboranesCyclooxygenase 2Cyclooxygenase 2 InhibitorsIodine RadioisotopesLipoxygenase Inhibitorscarboranesdual inhibitioneicosanoidsinflammationsingle‐photon emission computed tomography

Identifiers

PMID41918160
PMCPMC13039775

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.